Foundery Immune Studio, LLC Acquires Rights to a Suite of Next-Generation Clinical Stage Immunotherapies

On January 8, 2025 Foundery Immune Studio, LLC, a biotechnology venture studio focused on translating immunology discoveries into medicines, reported its acquisition of worldwide rights for three clinical-stage immune tuning therapies from Ikena Oncology, Inc (Press release, Ikena Oncology, JAN 8, 2025, View Source [SID1234649531]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Unlike existing and first-generation immunotherapies that exclusively target immune T cells, these monoclonal antibodies are engineered to precisely reconfigure the underpinnings of cancer immune responses. In particular, these therapies target the functions of myeloid cells, which are prevalent in all tissues and may constitute up to 50% of the total tumor cell population. By selectively targeting specific receptors on these myeloid cells, these therapies recalibrate the immune environment within tumors with greater precision. The evolving body of research on myeloid biology suggests TREM1, TREM2, and MARCO play crucial roles in cancer, fibrotic, autoimmune, and neurodegenerative diseases like Alzheimer’s.

Antibodies PY314 and PY159, targeting TREM2 and TREM1, respectively, completed Phase 1 trials and were well tolerated. Both antibodies demonstrated promising pharmacodynamic effects alone and in combination with pembrolizumab. The third program targeting MARCO, PY265, is Investigational New Drug (IND)-ready.

Foundery Immune Studio’s near-term focus is to refine the programs’ cancer applications and develop the programs in fibrotic and autoimmune diseases by launching its’ first subsidiary, RhBio, LLC.

"Tuning myeloid cells, rather than T cells, could revolutionize multiple diseases, as suggested by our research," said Matthew "Max" Krummel, PhD, founder of Pionyr Immunotherapies and co-discoverer of anti-CTLA-4 checkpoint blockade. "The immune phenotype of a tumor microenvironment, not the tissue of origin, appears to drive the response to these therapies, opening unexplored possibilities for treating cancers, autoimmune conditions, and inflammatory diseases."

Foundery Immune Studio’s founders Max Krummel, Michel Streuli, PhD, and Venkataraman Sriram, PhD, bring unique insight to the programs, having helped develop them at Pionyr Immunotherapeutics, Inc. The trio’s deep understanding of myeloid cell biology and extensive knowledge position them to advance these treatments in ways that have eluded others. They have individually contributed to groundbreaking commercialized therapies, including ipilimumab and pembrolizumab.

Cogent Biosciences Announces Presentation at the 43rd Annual J.P. Morgan Healthcare Conference

On January 8, 2025 Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, reported that Andrew Robbins, President and Chief Executive Officer, will present at the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco on Tuesday, January 14, 2025 at 7:30 a.m. PT/10:30 a.m. ET (Press release, Cogent Biosciences, JAN 8, 2025, View Source [SID1234649500]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live webcast will be available on the Investors & Media page of Cogent’s website at investors.cogentbio.com. A replay of the webcast will be available approximately two hours after the completion of the event and will be archived for up to 30 days.

EsoBiotec Doses First Patient in Investigator Initiated Trial of In Vivo BCMA CAR-T Candidate ESO-T01 for Multiple Myeloma

On January 08, 2025 EsoBiotec SA, a biotechnology company empowering cells in vivo to fight cancer, in collaboration with Pregene Biopharma, reported the first patient has been dosed in an investigator-initiated clinical trial in China of ESO-T01 for relapsed/refractory multiple myeloma (Press release, EsoBiotec, JAN 8, 2025, View Source [SID1234649799]). ESO-T01 is an immune shielded lentiviral vector that specifically reprograms T lymphocytes in vivo into highly effective BCMA CAR-T cells.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The multi-center, single arm, open-label, dose escalation clinical trial (NCT06691685) is designed to evaluate the safety, tolerability and preliminary clinical activity, including in vivo reprogramming efficiency of a single intravenous infusion, across escalating doses of ESO-T01 in up to 24 patients with multiple myeloma. Primary endpoints for the study include incidence and severity of cytokine release syndrome and immune effector cell-associated neurotoxicity syndrome, dose-limiting toxicities, and treatment-associated adverse effects.

"Initial clinical observations with ESO-T01 indicate a favorable safety profile and promising efficacy already at the first dose level of 0.25E+09 transducing unit per patient, with pharmacokinetic characteristics comparable to autologous ex vivo CAR-T therapies," said Principal Investigator Professor Heng MEI, Ph.D., M.D., Union Hospital, Tongji Medical College, Huazhong University of Science and Technology. "The first patient received a starting dose of ESO-T01 without prior lymphodepletion. By Day 28, minimal residual disease in the bone marrow was undetectable, and the elevated free light chain levels secreted by tumor cells had normalized. No significant adverse events were reported during treatment."

"ESO-T01 has the potential to offer a simplified patient journey, with several benefits over current treatments for multiple myeloma that are often costly and have unfavorable side effects," said EsoBiotec CEO Jean-Pierre Latere, Ph.D. "Our treatment does not require lymphodepletion, is immediately available to patients without any waiting time, and is administrated in a single intravenous dose that takes less than 10 minutes. This is why we value our collaboration with Pregene Biopharma to develop ESO-T01, as we share the common goal of making this groundbreaking treatment affordable and available to patients globally. We look forward to sharing initial clinical data in the second half of 2025."

"The clinical success of autologous CAR-T in treating hematologic malignancies is well established," said Pregene Biopharma Chief Executive Officer and co-founder Dr. Li Hongjian. "With in vivo delivery, more multiple myeloma patients can benefit from CAR-T. Moreover, we anticipate expanding to therapeutic areas such as autoimmune diseases, enabling broader patient access to effective treatment. Through this collaboration, we are pioneering innovative scientific advancements that have the potential to redefine the future of cell therapy."

ESO-T01 is the first in vivo BCMA CAR-T candidate to be dosed in a human clinical trial, and has been developed by EsoBiotec using its third-generation immune-shielded cell specific lentiviral vector platform, ENaBL, that reprograms immune cells inside the body. Combined with a BCMA CAR-T transgene developed by Pregene Biopharma and a robust industrial manufacturing process, ESO-T01 potentially represents a transformational therapeutic to provide patients with an off-the-shelf treatment at a cost of goods possibly one order of magnitude lower compared to ex vivo CAR-T therapy, which could redefine access to advanced therapies.

About ESO-T01

ESO-T01 is a third-generation replication-deficient self-inactivating lentiviral vector expressing a BCMA-targeted CAR construct under a T cell-specific synthetic promoter. It is immune shielded and resistant to phagocytosis. ESO-T01 is an "off-the-shelf" single dose treatment, directly administered systemically without the need for lymphodepletion.

About ENaBL Platform

EsoBiotec’s Engineered NanoBody Lentiviral (ENaBL) platform vectors are designed to specifically reprogram T cells and have demonstrated a high level of CAR T potency in animal studies. In large scale clinical manufacturing, the company has preserved vector specificity with high physical titer and high purity. EsoBiotec’s lead product candidate, ESO-T01, leverages the ENaBL platform to validate this novel technological approach using a clinically proven antigen.

Coherus Management to Present at the 43rd Annual J.P. Morgan Healthcare Conference

On January 8, 2025 Coherus BioSciences, Inc. ("Coherus," NASDAQ: CHRS) reported that senior management will present at the 43rd Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2025, at 5:15 p.m. Pacific Time (Press release, Coherus Biosciences, JAN 8, 2025, View Source [SID1234649501]). The presentation and Q&A session will be accessible via Webcast through a link posted on the Investor Events Calendar section of the Coherus website: View Source This webcast will be available for replay until February 10, 2025.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!


Samsung Biologics extends collaboration with LigaChem Biosciences for ADC development

On January 8, 2025 Samsung Biologics (KRX: 207940.KS), a global contract development and manufacturing organization (CDMO), reported to extend collaboration with LigaChem Biosciences (KOSDAQ: 141080) to provide antibody-drug conjugate (ADC) services (Press release, Samsung BioLogics, JAN 8, 2025, View Source [SID1234649517]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Samsung Biologics will support a series of LigaChem Biosciences’ ADC programs at Samsung Biologics’ new dedicated ADC facility. The two companies have already been collaborating on ADC programs for the treatment of solid tumors. LigaChem Biosciences is a biotech pioneering research and development of ADC candidates.

"The latest collaboration will further strengthen Samsung Biologics’ capabilities across all stages of ADC development and manufacturing as part of our commitment to deliver safe and high-quality therapeutics to patients," said John Rim, CEO and President of Samsung Biologics. "We look forward to supporting our clients’ innovative ADC pipelines, ensuring the highest quality and timelines are met."

"This collaboration with Samsung Biologics will be an important step toward strengthening the supply chain of high-quality ADC drugs and enhancing the competitiveness of both companies in the global ADC market," said Yong-Zu Kim, LCB’s President and CEO. "By leveraging Samsung Biologics’ extensive experience as a CDMO, we will accelerate the development of our pipeline and quickly provide innovative ADC treatments to patients".

Samsung Biologics’ ADC facility is a segregated suite, equipped with a 500-liter reactor, supporting the development and manufacture of ADC therapies. Building on the company’s track record of expertise in large-scale antibody manufacturing and process engineering, Samsung Biologics’ ADC service scope spans late discovery to development and conjugation.

Samsung Biologics has also been making active investments through the Samsung Life Science Fund in biotech companies pioneering ADC linker technologies, toolbox, and protein engineering.